Related Experiment Video
Updated: Jun 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
[A local control trial of skin malignant tumor]
Katsuhisa Enomoto1, Kenichi Sakurai, Sadao Amano
1Division of General, Breast and Endocrine and Respiratory Surgery, Department of Surgery, Nihon University School of Medicine.
Abstract:
Eighteen cases were diagnosed as skin malignant tumor in the past 4 years since 2005. We performed a sentinel lymph node biopsy and backup evidement for the 18 cases requiring a lymph node excision. Then, we reviewed its appropriateness. We also revealed interesting cases: Paget's out of breast 3, Merkel cell carcinoma 2, and malignant melanoma 13. The range of age was 37-73 year-old, and the male and female ratio was 12:6. The primary sites were external genitalia 3, femoral region 1, brachium part 3, finger region 2, digit region 3, sole region 3 and back 3. A sentinel lymph node (SLN) identification rate was 13/18 (72.2%). For the inferior limb nuclear power generation skin malignant tumor, the identification rate of SLN was 100%. There was only one identified of SLN for superior limb/the soma nuclear power generation skin malignant tumor. We thought that a reexamination of the regional lymph node and the lymph flow was necessary. With regard to the inferior limb nuclear power generation malignancy skin tumor, it was considered that the appropriateness of the sentinel lymph node by the pigment method was useful.
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)